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Abstract
Background: Chronic neuroinflammation is a hallmark of several neurological disorders associated with cognitive
loss. Activated microglia and secreted factors such as tumor necrosis factor (TNF)-a are key mediators of
neuroinflammation and may contribute to neuronal dysfunction. Our study was aimed to evaluate the therapeutic
potential of a novel analog of thalidomide, 3,6’-dithiothalidomide (DT), an agent with anti-TNF-a activity, in a
model of chronic neuroinflammation.
Methods: Lipopolysaccharide or artificial cerebrospinal fluid was infused into the fourth ventricle of three-month-old
rats for 28 days. Starting on day 29, animals received daily intraperitoneal injections of DT (56 mg/kg/day) or vehicle for
14 days. Thereafter, cognitive function was assessed by novel object recognition, novel place recognition and Morris
water maze, and animals were euthanized 25 min following water maze probe test evaluation.
Results: Chronic LPS-infusion was characterized by increased gene expression of the proinflammatory cytokines
TNF-a and IL-1b in the hippocampus. Treatment with DT normalized TNF-a levels back to control levels but not IL-
1b. Treatment with DT attenuated the expression of TLR2, TLR4, IRAK1 and Hmgb1, all genes involved in the TLR-
mediated signaling pathway associated with classical microglia activation. However DT did not impact the
numbers of MHC Class II immunoreactive cells. Chronic neuroinflammation impaired novel place recognition,
spatial learning and memory function; but it did not impact novel object recognition. Importantly, treatment with
DT restored cognitive function in LPS-infused animals and normalized the fraction of hippocampal neurons
expressing the plasticity-related immediate-early gene Arc.
Conclusion: Our data demonstrate that the TNF-a synthesis inhibitor DT can significantly reverse hippocampus-
dependent cognitive deficits induced by chronic neuroinflammation. These results suggest that TNF-a is a critical
mediator of chronic neuroinflammation-induced neuronal dysfunction and cognitive impairment and targeting its
synthesis could provide an effective therapeutic approach to several human neurodegenerative diseases.
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Background
Microglia activation is present during the early stages of
many neurodegenerative conditions, such as Alzheimer’s
disease, Parkinson’s disease and HIV-associated demen-
tia [1-3]. Microglia are the resident innate immune cells
of the central nervous system (CNS) and are critical in
the early response and defense against insults that can
impact the CNS. Microglia monitor their environment
through a variety of pattern recognition receptors that
respond to pathogen- or damage-associated molecular
pattern stimuli, such as lipopolysaccharide (LPS) [4-6]
and b-amyloid peptide [7-9]. Important as a first line of
defense upon recognition of stressor stimuli, activated
microglia accumulate at sites of tissue damage and
express genes related to inflammation, such as proin-
flammatory cytokines and chemokines. Their over
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stimulation may, however, further activate inflammatory
responses and thus potentiate a self-sustained cycle of
unregulated inflammation [10]. Although microglia acti-
vation is required to guarantee CNS integrity, it has
become clear that unregulated inflammatory responses
and the release of proinflammatory molecules are
responsible for neurotoxic processes in several neurode-
generative conditions. Laboratory data demonstrate that
sustained microglia activation induced by LPS through
the toll-like receptor (TLR)-4 mediated signaling path-
way [5] results in an altered neuronal pattern of synaptic
plasticity-related gene expression [11-14] and cognitive
impairment in rodents [15,16].
Tumor necrosis factor (TNF)-a is a potent proinflam-
matory cytokine that plays a central role in initiating
and sustaining the inflammatory response. TNF-a is
generated as a transmembrane 26-kDa precursor mole-
cule that is proteolytically cleaved to yield a soluble 17-
kDa TNF-a protein that subsequently generates a non-
covalently linked homotrimer in solution. Both mem-
brane-bound and soluble forms of TNF-a are biologi-
cally active, signaling through two different
transmembrane spanning receptor (R) subtypes, TNF-R1
and TNF-R2. TNF-a signaling has been shown to pro-
vide several important functions within the CNS [17]
including regulation of microglial activation [18], regula-
tion of glutamatergic transmission [19] and control of
synaptic strength [20]. Elevated levels of TNF-a have
been documented in several neurodegenerative disorders
including Alzheimer’s disease [21-24], Parkinson’s dis-
ease [25,26] and HIV-associated dementia [27]. Hence,
the regulation of TNF-a signaling may prove to be ben-
eficial in the context of neurodegenerative disorders
associated with neuroinflammation [28].
In accord with this, rapid clinical improvements in
cognitive function have been described in subjects with
Alzheimer’s disease following intraspinal administration
of the TNF-a-blocking agent etanercept, followed by
Trendelenburg positioning [29-31]. Although a thera-
peutically relevant reduction of TNF-a signaling may be
achieved by the use of such a protein based agent, its
potential widespread utility in the broad context of neu-
rological disorders may be limited consequent to its
restricted passage across the blood-brain barrier. As an
achievable alternative approach, the use of small lipophi-
lic molecules possessing the ability to both inhibit TNF-
a synthesis and penetrate the blood-brain barrier would
be of significant value. 3,6’-dithiothalidomide (DT) is an
isosteric analog of thalidomide (N-a-phthalimidoglutari-
mide), which has been reported to reduce the rate of
TNF-a synthesis through enhanced degradation of its
transcript [32,33]. DT possesses a TNF-a lowering
action that proved more potent than equimolar thalido-
mide in both LPS-stimulated RAW 264.7 cells [34] and
LPS-stimulated human peripheral blood mononuclear
cells [35,36]. The in vitro TNF-a protein lowering prop-
erties of 3,6’-dithiothalidomide have been shown to
translate into an in vivo setting where the agent amelio-
rated the increase in TNF-a protein levels induced by
an acute peripheral LPS administration in rodent [37].
The present study was designed to investigate the thera-
peutic potential of DT in treating the consequences of
chronic neuroinflammation using a relevant and well-
established rat model displaying LPS-induced sustained




The DT compound was synthesized by WL according to
a published procedure [40] to greater than 99.8% chemi-
cal purity. For dosing purposes, it was prepared as a sus-
pension in 1% carboxymethyl cellulose to provide a final
concentration of 56 mg/kg (equimolar to 50 mg/kg of
thalidomide) and was administered by the intraperito-
neal (i.p.) route (0.1 mL/100 g body weight injection).
Animal procedures
This research was conducted under the supervision and
with the approval of the University of California Institu-
tional Animal Care and Use Committee. Twenty-eight
3-month-old male F344 rats (Charles River Labs) were
used in this study. All rats were individually caged and
maintained in a temperature- (22 ± 1°C) and light-con-
trolled environment with an artificial 12 h light/dark
cycle (lights off at 8 a.m. and on at 8 p.m.), with food
and water freely available. As previously described, artifi-
cial cerebrospinal fluid (aCSF; n = 11) or lipopolysac-
charide (LPS; n = 17; Sigma-Aldrich, E.coli, serotype
055:B5, TCA extraction, 1.0 μg/μl dissolved in aCSF)
were loaded into an osmotic minipump (Alzet model
#2004, 0.25 μl/h; 28-day delivery) and chronically
infused for 28 days through a cannula implanted into
the fourth ventricle of the brain [11-13,16]. At 29 days
after surgery and the day following the end of chronic
infusion, nine rats from the LPS-infused groups and five
rats from the aCSF-infused group received DT via intra-
peritoneal injection for a duration of 14 days. In addi-
tion, eight rats from the LPS-infused groups and six rats
from the aCSF-infused group were injected with 1% car-
boxymethyl cellulose alone. Rats were handled daily for
10 days prior to behavioral assessment. Behavioral
manipulations and testing were carried out during the
dark phase of the light cycle. Novel place and novel
object recognition testing were performed from days 39
to 42 post-surgery and Morris water maze from days 44
to 48 post-surgery, as described in detail below. Each rat
was euthanized by deep anesthesia followed by
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decapitation 25 min after completion of the probe trial
of the Morris water maze and the brain was quickly
removed and divided at the midline. One brain hemi-
sphere was immediately frozen in -70°C isopentane
(Sigma-Aldrich) for histological analysis and the hippo-
campus of other hemisphere was removed at 4°C and
stored at -70°C for further RNA extraction. The same
experimenter dissected all the samples for consistency.
Novel place and novel object recognition test
An open field arena (60 × 60 cm square with 20 cm
high walls) was placed in a dimly lit behavioral testing
room. Large visual cues were placed on the walls of the
testing room at various locations to provide spatial
points of reference for the animals. Trials were recorded
using an overhead camera and live tracking of the ani-
mals was achieved using an automated video tracking
system (Ethovision XT; Noldus Information Technol-
ogy). Exploratory behavior, defined as the animal direct-
ing its nose toward an object at a distance within a 4-
cm radius, was analyzed during the first minute on each
test unless specified. Data are expressed as the percent
time spent exploring the target object ([time exploring-
target]/[time exploring target + time exploring non -
target object] × 100); where the target object is repre-
sented by the relocated object during the place recogni-
tion task and by the novel object during the object
recognition task. The arena and objects were cleaned
with 0.025% bleach between trials to minimize odor
cues.
Novel place recognition
On assessment Days 1 and 2, rats were allowed to
explore the open field arena for one 15 min period
(habituation phase). On Day 3, two identical objects (A)
were placed in opposite corners of the arena and
secured to the floor using Velcro. Animals were allowed
to explore the objects for 5 min (familiarization phase)
and were then placed back in their cage for 5 min while
one of the objects was moved to a new location within
the arena (novel place/target object). Animals were then
reintroduced into the open arena to explore for 5 min.
The 24-h delay novel place/target object recognition test
was conducted on day 4. The target object was moved
to the remaining new location and the rats were allowed
to explore for 5 min.
Novel object recognition
For the novel object recognition task, two identical
objects (B) were placed in the two corners/locations not
used during the 24-h delay novel place recognition test.
The animals were allowed to explore these objects for 5
min and returned to their cage for 5 min while one of
the objects was replaced with a novel object (C, novel
object/target object). Thereafter, animals were reintro-
duced into the box to explore for a further 5 min.
Morris water maze test
A blue plastic tank/pool (160 cm diameter) was placed
in a dimly lit behavioral testing room. Visual cues were
placed around the room as spatial references. A trans-
parent platform (12 cm diameter) was placed in the
tank and water was added until the platform was sub-
merged 1 cm below the surface. The test consisted of
three phases: visible platform training, hidden platform
training and a probe test.
Visible platform training took place on Day 1. A visi-
ble flag was installed on the escape platform, allowing
the rat to visualize the location of the platform. Each rat
performed a total of 4 visible platform trials, in which
the rats learned to identify the visible platform when it
was placed at different locations in each trial. A rat that
failed to locate the platform within the allotted time was
immediately guided to the platform manually. Once the
rat reached the platform, it remained there for 20 s
before removal from the water maze. Each rat was then
towel-dried and returned to a heated incubator (25°C)
to prevent hypothermia.
Hidden platform training took place on Days 2-4. Room
and pool setup were identical to those of the visible plat-
form training, with the exception that the flag was removed
from the escape platform and the hidden platform was
consistently located in the same location throughout all
trials. All rats performed three training blocks per day
(with two consecutive training trials per block) for 3 days
(18 trials total), with the tank/pool insertion point location
changing randomly from trial to trial. The maximum trial
duration was 60 s, after which animals were manually
guided to the platform in the event that they failed to
locate it. Once animals reached the platform, they were
allowed to remain there for 20 s. Animals were allowed a
60 s inter-trial interval within a given training block, and
60 min of recovery time between training blocks.
As a final assessment a probe trial was conducted on
Day 5, 24 h after the last trial performed on Day 4. The
platform was removed and animals were allowed to
swim freely for 60 s. The percentage of time spent in
each quadrant of the maze was then recorded. Specifi-
cally, an Ethovision automated video tracking system
(Noldus Information Technology) monitored all perfor-
mances in the following parameters: average velocity,
escape latency and duration spent in each quadrant.
RNA extraction and real-time RT-PCR analysis
The left hippocampus from each rat was processed for
total RNA extraction and purification using the RNeasy
Lipid Tissue Mini Kit (Qiagen). One microgram of total
RNA was reverse-transcribed using the High-Capacity
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cDNA reverse transcription kit (Applied Biosystems).
Quantitative real-time RT-PCR analysis was performed
on Mx3005P QPCR System (Agilent Technologies)
using Brilliant II SYBR Green reagents (Stratagene). The
thermal cycler conditions were as follows: hold for 10
min at 95°C, followed by 40 cycles of a two-step PCR
consisting of a 95°C step for 30 s followed by a 60°C
step for 1 min. Primer sequences are presented in Table
1. Amplifications were carried out in triplicate and the
relative expression of target genes was determined by
the DDCT method, using cyclophilin gene expression as
an internal control to normalize the results.
Histological procedures
The right brain hemispheres were blocked, as previously
described [11,12,16], such that each block contained a half
hemisphere from one rat from each experimental group.
These blocks were then cryosectioned at a thickness of 20
μm and collected on microscopic slides. All slides were
stored at -70°C until processed for immunohistochemistry.
Three sections selected from the medial portion of the
dorsal hippocampus (from 3.2 to 4.00 mm posterior to
bregma) were stained for immunoreactive microglia using
an antibody for major histocompatibility complex class II
(MHC Class II RT1B mouse monoclonal antibody clone
OX-6; BD Pharmingen) as previously described [11]. Six
to eight additional slides from the same medial portion of
the dorsal hippocampus were stained for Arc (activity-
regulated cytoskeleton-associated protein) protein (rabbit
polyclonal antibody; generously supplied by P.F. Worley’s
laboratory), as previously described [11].
Image acquisition and analysis
Z-stack images (200× magnification; 1 μm optical thick-
ness per plane; 8 planes) were taken using a Zeiss Apo-
tome microscope and offline analyses were performed
using Zeiss AxioVision software. The density of MHC
class II immunoreactive cells and the percentage Arc
immunoreactive neurons within the dentate gyrus (DG),
and the CA1 and the CA3 areas of the hippocampus
were then measured blindly to the experimental group,
as described in detail previously [11,16].
Statistics
Data are presented as means ± SEM. Differences
between mean values were determined using t-test or
one-way analysis of variance (ANOVA) procedures with
Newman-Keuls tests for post hoc comparison. The
learning curve of the Morris water maze hidden plat-
form training was analyzed with a two-way ANOVA
with day and experimental group as independent factors
and with Newman-Keuls tests for post hoc comparison.
Values of p < 0.05 are considered to be statistically sig-
nificant. Data were analyzed and graphs were plotted by
GraphPad Prism software version 5.0.
Results
Chronic LPS infusion was well tolerated by all rats, in
accord with previous studies [11]. Albeit that LPS-
infused animals lost a few grams body weight immedi-
ately after surgery, all recovered within a few days and
continued to gain weight normally for the duration of
the study. Treatment with DT was well tolerated and,
unlike thalidomide that is associated with soporific
actions, did not impact spontaneous locomotion activity,
open field exploration or other motor behaviors, such as
swimming in the Morris water maze.
Treatment with 3,6’-dithiothalidomide normalized TNF-a
but not IL-1b levels
TNF-a expression in the hippocampus was assessed at
the transcript level using real time PCR analysis (Figure
Table 1 Primer sequences
Gene GenBank accession number Forward primer 5’®3’ Reverse primer 5’®3’
CD200 AF231392 GTCCTTGGATGGGCATTTA TGCGGAGATTCACCACAA
Cyclophilin NM_017101 AGCATACAGGTCCTGGCATC TTCACCTTCCCAAAGACCAC
CX3CL1 NM_134455.1 ATCCCAGTGACCTTGCTCATCC AAGTGTCTGTGCTGTCTCGTCTCC
Hmgb1 NM_012963 GAGCACAAGAAGAAGCACCC TAACGAGCCTTGTCAGCCTT
IL-1b NM_031512 CACCTCTCAAGCAGAGCACAGA ACGGGTTCCATGGTGAAGTC
IL-4 NM_201270 CAGGGTGCTTCGCAAATTTT CTCAGTTCACCGAGAACCCC
IL-6 NM_012589 GCCAGAGTCATTCAGAGCAA CATTGGAAGTTGGGGTAGGA
IRAK1 NM_001127555 ACCTCCCTGGAAGCTAGAGG AGAGGCCAGGAACACTCTCA
NfB p65 NM_199267 ACGATCTGTTTCCCCTCATCT TGCTTCTCTCCCCAGGAATA
TLR2 NM_198769 TGGAGACTCTGGAAGCAGGT CGCCTAAGAGCAGGATCAAC
TLR4 NM_019178 GAGGACTGGGTGAGAAACGA AGATACACCAACGGCTCTG
TNF-a NM_013693 GTGATCGGTCCCAACAAG AGGGTCTGGGCCATGGAA
TNFR1 NM_013091 GCTGCACCAAGTGCCACAA TCACACACCTCGCAGACTGTTTC
TNFR2 NM_130426 CACACATCCCTGTGTCCTTG AAGCAGTTCGCCAGTCCTAA
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1). TNF-a mRNA levels were significantly elevated in
LPS-vehicle rats as compared with aCSF-vehicle rats
(129.97 ± 9.09%; p < 0.05 vs. aCSF-vehicle). Treatment
with DT returned TNF-a mRNA to control levels
(102.18 ± 8.90%; p < 0.05 vs. LPS-vehicle). Analysis of
TNF-a receptors mRNA levels revealed that TNFR2 but
not TNFR1 expression was significantly elevated in LPS-
vehicle rats, as compared to aCSF-vehicle rats (124.91 ±
6.25%; p < 0.05 vs. aCSF-vehicle). Importantly, DT treat-
ment decreased TNFR2 mRNA back to control levels
(101.45 ± 6.46%; p < 0.01 vs. LPS-vehicle; not significant
vs. aCSF-vehicle). IL-1b mRNA levels were significantly
increased in both LPS-vehicle and LPS-DT rats, as com-
pared with aCSF-vehicle rats (580.0 ± 89.36%; p < 0.001
and 399.3 ± 47.50%; p < 0.05 vs. aCSF-vehicle rats,
respectively). However, treatment with DT in LPS-DT
rats significantly attenuated IL-1b mRNA levels com-
pared to the LPS-vehicle rats (p < 0.05). No significant
differences were observed in the levels of the proinflam-
matory cytokine IL-6, the anti-inflammatory cytokine
IL-4 or the chemokines CX3CL1 and CD200 for any
treatment group (Figure 1). Together, our data demon-
strate that treatment with DT significantly decreased
LPS-induced elevations in gene transcripts for TNF-a
and its receptor type 2 (TNFR2) and, to a lesser degree,
IL-1b in the setting of chronic neuroinflammation.
Interestingly, treatment with DT did not induce any sig-
nificant changes in transcript measurements in the
absence of an LPS-induced alteration in gene expression.
Treatment with 3,6’-dithiothalidomide did not affect the
numbers of MHC class II positive cells in the
hippocampus
Quantitative cell count analysis of OX-6 immunoreac-
tive microglia revealed a significant increase of the num-
ber of MHC class II positive cells per square millimeter
in the DG and CA3 areas of LPS-vehicle (59.91 ± 9.63
and 42.02 ± 6.37, respectively; p < 0.01 vs. aCSF-vehicle
and aCSF-DT for both) and LPS-DT rats (51.81 ± 12.69
and 41.64 ± 7.46, respectively; p < 0.01 vs. aCSF-vehicle
and aCSF-DT for both) (Figure 2). Importantly, the den-
sity of MHC Class II positive microglia did not differ
between LPS-vehicle and LPS-DT in either the DG or
the CA3. Very few MHC class II positive microglia were
observed around the CA1 area of the hippocampus of
LPS-vehicle (2.73 ± 1.01) and LPS-DT rats (2.41 ± 0.68)
and no significant differences were observed across all
four groups (data not shown). Our data show that DT
Figure 1 Cytokine and chemokine gene expression. TNF-a mRNA levels in the hippocampus were significantly elevated in LPS-vehicle rats
(*p < 0.05 vs. aCSF-vehicle rats) and reduced to control levels in LPS-DT rats (#p < 0.05 vs. aCSF-vehicle rats). TNFR2 mRNA levels were
significantly elevated in LPS-vehicle rats (*p < 0.05 vs. aCSF-vehicle) and similarly lowered to control levels in LPS-DT rats (##p < 0.01 vs. LPS-
vehicle; not significant vs. aCSF-vehicle). IL-1b mRNA levels were significantly increased compared to aCSF-V levels in both LPS-vehicle and LPS-
DT groups (***p < 0.001 and *p < 0.05 vs. aCSF-vehicle rats). However, DT treatment did induce a significant reduction in the gene transcript
level compared to the LPS-vehicle group (#p < 0.05 vs. LPS-vehicle rats). Treatment with LPS and/or DT induced no significant differences in
gene transcript levels for IL-6, IL-4 and CX3CL1 and CD200.
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treatment had no impact on altering the numbers of
MHC class II positively stained microglia cells following
their activation by chronic LPS infusion.
Inhibition of TNF-a mRNA by 3,6-dithiothalidomide was
paralleled by reduced expression of genes involved in
TLR-mediated signaling pathways
LPS is known to activate microglia primarily through
the pattern recognition receptor TLR4 signaling pathway
[4-6]. We therefore assessed the gene expression of fac-
tors involved in TLR-mediated signaling pathways which
have been reported to be indicative of microglia activa-
tion following a central immune challenge [41,42] (Fig-
ure 3). TLR2 and TLR4 expression were increased in
the hippocampus of LPS-vehicle rats (152.58 ± 8.89 and
118.95 ± 4.23%; p < 0.001 and p < 0.05 vs. aCSF-vehicle,
respectively). Treatment with DT (i) normalized both
TLR2 and TLR4 expression in LPS-DT rats (112.92 ±
5.71 and 98.47 ± 2.44%; p < 0.001 and p < 0.05 vs. LPS-
vehicle, respectively; but not significant vs. aCSF-vehi-
cle), (ii) decreased the expression of the endogenous
TLR4 ligand Hmgb1 in LPS-DT rats compared with
LPS-vehicle rats (86.63 ± 2.87 vs. 100.27 ± 1.74%; p <
0.05);, and (iii) reduced the expression of the enzyme,
IRAK1, known to transduce signaling from TLRs in
both aCSF-DT (80.59 ± 3.16 vs. 100.00 ± 2.73% in
aCSF-vehicle; p < 0.05) and LPS-DT rats (82.35 ± 4.29
vs. 93.44 vs. ± 3.65% in LPS-vehicle; p < 0.05). Though
MyD88 and NFB p65 expression levels tended to be
decreased in both aCSF-DT and LPS-DT, as compared
with their respective control, statistical significance was
not reached. Overall these data demonstrate that treat-
ment with DT resulted in a lowered expression of sev-
eral markers of the TLR-mediated signaling pathway.
Treatment with 3,6’-dithiothalidomide rescued
neuroinflammation-induced impairment in 5-min delay
but not 24-h delay novel place recognition
Exploration during the novel place recognition
familiarization phase
Analysis of the total time duration spent exploring in
the open arena during the initial object-exploration
familiarization phase revealed no significant difference
between aCSF-vehicle (24.93 ± 3.64 s), aCSF-DT (26.03
± 2.00s), LPS-vehicle (29.34 ± 2.97 s) and LPS-DT
(38.60 ± 5.32 s) (p = 0.0965; Figure 4A).
Novel place object recognition test (5 min delay)
Animals from the aCSF-vehicle and aCSF-DT groups
showed a preference for exploration of the object in the
novel place over the familiar place (82.30 ± 9.39%; p =
0.0012 vs. familiar place; 72.21 ± 10.09%; p = 0.0144 vs.
familiar place; respectively, Figure 4B). Interestingly, the
LPS-vehicle group showed no overall preference to
objects in either location (50.90 ± 6.98%; p = 0.86 vs.
familiar place). Of relevance, the LPS-DT animals dis-
played a preference to the object placed in the novel
location, which is more akin to the behavior of control
animals (62.76 ± 8.18%; p = 0.0445 vs. familiar place).
These data suggest that DT treatment rescued neuroin-
flammation-induced impairment in the novel place
object recognition assessment after a 5-min delay inter-
val. Analysis of the cumulated exploration duration
(novel + familiar location) showed no significant differ-
ences between groups (data not shown).
Novel place object recognition test (24 h delay)
Similar to that observed in the 5 min delay interval
groups, aCSF-vehicle and aCSF-DT animals displayed a
preference for the novel object place rather than the
familiar object place (68.70 ± 10.39%; p = 0.0216; 69.43
± 5.49%; p = 0.0005; respectively) (Figure 4C). However,
in contrast to the 5 min delay interval, both the LPS-
vehicle and LPS-DT groups showed no preference for
the novel object place over the familiar object location
(50.02 ± 9.32%; p = 0.9981; 52.09 ± 12.90%; p = 8219;
respectively, Figure 4C). Analysis of the cumulated
exploration duration (novel + familiar location) showed
no significant differences between groups (data not
shown).
Novel object recognition test was not affected by chronic
neuroinflammation
Exploration during the novel object recognition
familiarization phase
Analysis of the total time spent in exploration of the
objects in the open arena during the novel object recog-
nition familiarization phase revealed no significant dif-
ference between groups (data not shown).
Figure 2 OX-6 immunoreactive microglia staining. Staining from
the LPS-vehicle and LPS-DT rats displayed elevated numbers of OX-
6 immunoreactive microglia per square millimeter within the DG
and CA3 regions of the hippocampus (**p < 0.01 vs. aCSF-veh). No
significant difference was observed between LPS-vehicle and LPS-DT
rats.
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Figure 3 TLR-mediated signaling pathway related gene expression. Real time RT-PCR analysis from the hippocampus revealed that the
gene expressions of TLR2 and TLR4 were increased in LPS-vehicle rats (***p < 0.001 and *p < 0.05 vs. aCSF-vehicle rats), while treatment with
DT restored expression levels back to control (###p < 0.001 and #p < 0.05 vs. LPS-vehicle). Whereas LPS had no effect on Hmgb1 expression,
treatment of LPS infused animals with DT decreased the expression of Hmgb1 (#p < 0.05 vs. LPS-vehicle). Treatment with DT reduced the
expression of IRAK1 in both aCSF-DT and LPS-DT rats ($p > 0.05 vs. aCSF-vehicle and #p < 0.05 vs. LPS-vehicle). No significant differences in
hippocampal transcript levels of MyD88 or NFB p65 were observed between the treatment groups.
Figure 4 Novel place and novel object recognition test. (A). Novel place recognition familiarization phase. Analysis of the total amount of
object exploration showed no significant difference across experimental groups. (B). 5 min delay novel place recognition. aCSF-vehicle, aCSF-DT
and LPS-DT rats showed a preference for the novel place recognition over the familiar location (*p < 0.05 and **p < 0.01 vs. familiar place)
whereas LPS-vehicle rats did not. (C). 24 h delay novel place recognition. aCSF-vehicle and aCSF-DT showed a preference for the novel place
recognition over the familiar location (*p < 0.05 and ***p < 0.001 vs. familiar place) whereas LPS-vehicle and LPS-DT rats did not (D). Novel
object recognition. aCSF-vehicle, aCSF-DT, LPS-vehicle and LPS-DT rats all showed a preference for the novel object over the familiar one (*p <
0.05; **p < 0.01; ***p < 0.001 vs. familiar object).
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Novel object recognition test (5 min delay)
Short-term novel object recognition was used to assess
hippocampus-independent memory [43,44]. All animals
across treatment groups showed a significant discrimi-
nation between the novel and familiar objects, spending
a significantly higher percentage of time exploring the
novel object over the familiar one (aCSF-vehicle: 82.65
± 9.89; p = 0.0016; aCSF-DT: 87.67 ± 12.33; p = 0.0124;
LPS-vehicle: 90.52 ± 2.89; p < 0.0001; LPS-DT: 66.28 ±
7.46; p = 0.0094 vs. familiar place), thereby indicating
that neither neuroinflammation nor treatment with DT
altered novel object recognition (Figure 4D).
Treatment with 3,6’-dithiothalidomide restored
acquisition and consolidation of spatial memory
Visible platform training
All treatment groups (aCSF-vehicle, aCSF-DT, LPS-vehi-
cle and LPS-DT) displayed a similar swim velocity
(24.08 ± 0.81; 23.15 ± 1.07; 23.09 ± 0.64 and 24.10 ±
0.69 s/m, respectively; p = 0.6878) and similar escape
latency to locate the platform (36.10 ± 3.51; 30.00 ±
5.62; 36.33 ± 4.44 and 34.78 ± 4.86 s, respectively; p =
0.7775), suggesting that neither LPS or DT treatment
induced any impairments in motor function or visual
acuity to find the platform (Figure 5A).
Hidden platform training
Interestingly, animals form the aCSF-vehicle, aCSF-DT
and LPS-DT groups showed daily improvements in their
abilities to locate the hidden platform during the acqui-
sition phase of the Morris water maze task, whereas
LPS-vehicle rats showed an impaired learning profile
(Figure 5B). This delayed learning of LPS-vehicle versus
aCSF-vehicle rats, was significant on the second (p <
0.05) and third days (p < 0.001) of the hidden platform
training. The improved learning of LPS-DT rats, com-
pared with LPS-vehicle rats was significant on the third
day of training (p < 0.01). These disparities were not
caused by differences in swim speed (data not shown).
Probe test
Findings from the probe test indicate that animals from
the aCSF-vehicle, aCSF-DT and LPS-DT groups spent a
significantly higher percentage of time in the target
quadrant (the location that contained the platform dur-
ing training) as opposed to the other equivalent zones
(44.22 ± 2.78%; 53.63 ± 3.74; 46.79 ± 4.52%; p < 0.0001
vs. other quadrants for both). In contrast, the LPS-vehi-
cle group failed to show significant discrimination
between any quadrant (p = 0.0932, Figure 5C).
Treatment with 3,6’-dithiothalidomide normalized the
expression of the plasticity-related arc in the
hippocampus
To establish how neuroinflammation affected cognitive
information processing and the subsequent effects of
treatment with DT, we analyzed the proportion of neu-
rons expressing the plasticity-related immediate early
gene Arc after the 24 h probe test trial in the DG, CA1
and CA3 areas of the hippocampus (Figure 6). The per-
cent of neurons expressing Arc within the LPS-vehicle
group showed an elevated trend, as compared to the
aCSF-vehicle group, in all the areas analyzed that
Figure 5 Morris water maze test. (A). Visible platform training.
There was no significant group difference in average swim velocity
or escape latency to the platform (B). Hidden platform training.
aCSF-vehicle, aCSF-DT and LPS-DT groups improved their daily
performance during the acquisition phase of the Morris water maze
task, whereas LPS-vehicle rats showed an impaired learning profile.
The average escape latency of LPS-vehicle rats was significantly
higher than that of aCSF-vehicle animals on the second (*p < 0.05)
and third day (***p < 0.001). The average escape latency of LPS-DT
rats did not significantly differ from aCSF-vehicle rats, and was
significantly lower than that of LPS-vehicle animals on the third day
of training (##p < 0.01). (C). Probe test. aCSF-vehicle, aCSF-DT and
LPS-DT groups spent a significantly higher percentage of time in
the target quadrant than the other quadrants (***p < 0.001 vs. other
quadrants) whereas LPS-vehicle rats did not.
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reached statistical significance in the CA3 area (40.59 ±
3.74 in LPS-vehicle vs. 28.95 ± 3.74% in aCSF-vehicle; p
< 0.05). In LPS-DT rats, the percent of neurons expres-
sing behaviorally-induced Arc protein within the DG,
the CA1 and the CA3 was lower than that observed in
LPS-vehicle animals, with statistical significance similarly
observed in the CA3 (27.89 ± 3.37%; p < 0.05 vs. LPS-
vehicle).
Discussion
Chronic neuroinflammation is consistently present dur-
ing the early stages of Alzheimer’s disease and HIV-
associated dementia and likely contributes to the cogni-
tive dysfunction associated with these disorders and
drives disease progression [1,45-47]. It has hence
become important to understand the mechanisms
underlying chronic neuroinflammation-induced cogni-
tive impairments and to explore potential therapeutic
approaches to ameliorate them. Chronic neuroinflam-
mation can be reliably reproduced in rodents by the
slow, continuous infusion of a low dose of LPS into the
brain, and such models are associated with impaired
spatial cognitive function [11,15,16]. Herein we were
able to demonstrate that the blood-brain barrier per-
meant TNF-a lowering agent, DT, effectively rescued
hippocampus-dependent cognitive impairment induced
by chronic neuroinflammation. The decrease in TNF-a
mRNA was paralleled with a normalization of the
inflammation-induced disproportionate expression of
the plasticity-related immediate-early-gene Arc. These
data suggest that the proinflammatory cytokine TNF-a
signaling is critically involved in the disruption of pat-
terns of hippocampal activity underlying learning and
memory and that inhibition of TNF-a synthesis can
restore cognitive function from a behavioral and cellular
prospective.
Chronic neuroinflammation is characterized by a long-
standing activation of immune cells and subsequent sus-
tained release of proinflammatory factors. Here chronic
neuroinflammation was induced by slow intraventricular
infusion of LPS, a component of the outer membrane of
Gram-negative bacteria, known to selectively activate
microglial cells through the stimulation of TLR4/CD14
receptors [4-6]. This treatment gave rise to a long-last-
ing innate immune response that persisted in the hippo-
campus even following discontinuation of LPS infusion,
as evidenced by increased gene expression of the inflam-
matory markers TNF-a, IL-1b, TLR2 and TLR4. DT was
administered after discontinuation of LPS infusion to
define the ability of the compound to reverse neuronal
dysfunction and cognitive impairments induced by self-
sustained chronic neuroinflammation.
Moreira and co-workers described that thalidomide
reduced the half-life of TNF-a mRNA by approximately
50% [32]. Latterly, Zhu and Greig and co-workers illu-
strated that thiol analogs of thalidomide, including DT,
were more potent than thalidomide at lowering LPS sti-
mulated TNF-a protein secretion in vitro. Additionally,
the thiol analogs were found to share the same mechan-
ism of action to that of thalidomide where the agents
acted upon the 3’-UTR of TNF-a mRNA [35,36]. Inter-
estingly, several protein mRNA’s are subject to regula-
tion at the 3’-UTR region via actions upon adenylate/
uridylate (AU)-rich elements. TNF-a mRNA is known
to be regulated by several RNA binding proteins such as
HuR which stabilizes RNA and effectively increase the
translation efficiency of the cytokine [48], tristetraprolin
and AUF1 both of which destabilize RNA and thus
Figure 6 Proportion of neurons expressing Arc in response to behavior. The proportion of pyramidal neurons expressing behaviorally-
induced Arc in the CA3 area was significantly increased in LPS-vehicle animals (*p < 0.05 vs. aCSF-vehicle). DT normalized this proportion back
to control levels in LPS-DT rats (#p < 0.05 vs. LPS-vehicle). Similar trends were observed in the DG and the CA1 area, albeit statistical significance
was not achieved.
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reduce the translation of RNA into protein [49,50]. Both
HuR and tristetraprolin are regulated by p38 mitogen-
activated protein kinase (p38 MAPK) and p38 MAPK
has been shown to be inhibited by thalidomide [51,52].
It is likely that DT acts in a similar manner, however
additional studies will be required to establish this.
The chosen dose and duration of DT administration
were based on preliminary results showing that 14 days
of DT administration (56 mg/kg/day; i.p.) reduced
microglia activation and prevented cognitive impair-
ments induced by concomitant LPS infusion (Tweedie
D, Rosi S, Greig NH, unpublished work). The dose of
DT (56 mg/kg, equimolar to 50 mg/kg of thalidomide)
compares favorably with those of thalidomide used in
humans, where doses of up to 1200 mg are adminis-
tered. Hippocampal gene expression analysis showed a
normalization of TNF-a levels in LPS-infused rats trea-
ted with DT and confirmed the compound’s ability to
access the CNS and to act as a TNF-a synthesis inhibi-
tor, in line with previous studies [34-37]. The increase
in TNF-a levels and its normalization by DT were par-
alleled by similar modulation of TNFR2. TNFR2 is
known to be expressed primarily by cells of the immune
system (including microglia) and by endothelial cells
and to act via a number of different signaling pathways
to increase NFB-mediated transcription of anti-apopto-
tic and pro-inflammatory gene targets [17,53]. The nor-
malization of TNF-a by DT was not associated with
major variations of other cytokines and chemokines
known to regulate inflammation (IL-1b, IL-6, IL-4,
CD200 and CX3CL1). Importantly, IL-1b levels
remained significantly elevated, suggesting that DT
effects were mediated primarily through TNF-a but not
IL-1b mediated signaling pathway inhibition.
TNF-a has been shown to promote the proliferation
and activation of microglia cells [17,18]. Therefore, we
investigated whether microglia activation could be modi-
fied by DT treatment, after the initiation and onset of
microglial activation. We observed that DT treatment
did not impact the number of MHC-Class II positive
microglia accumulated within the DG and CA3 regions
of the hippocampus in response to prior LPS-infusion.
The elevated expression of genes involved in the TLR-
mediated signaling pathways has been reported to be
indicative of classical microglia activation following a
central immune challenge [41,42]; in line with these
findings, our data showed increased expression of TLR2
and TLR4 levels in LPS-vehicle rats. Importantly, nor-
malization of TNF-a transcripts by DT was paralleled
by a significant decline in the expression of several
genes involved within the TLR mediated signaling path-
ways, such as TLR2, TLR4, Hmgb1 and IRAK1. As it is
established that TLR-mediated signaling pathway activa-
tion leads to increased TNF-a expression [54], we can
hypothesize that this, in turn, contributed to the
decrease in TNF-a expression observed in our experi-
ment. As MHC class II expression can also occur in
microglia that are alternatively activated to produce
anti-inflammatory cytokines, we also studied the expres-
sion of the anti-inflammatory cytokine IL-4; however no
differences were observed across treatment groups. Our
findings suggest that the decrease of TNF-a led to an
attenuated expression of genes involved within the TLR-
mediated signaling pathway associated with classical
microglia activation.
Rats with chronic neuroinflammation displayed
impaired performances in both novel place recognition
and spatial learning and memory retention tests, but not
in the novel object recognition test. The processing of
spatial recognition memory and the ability to remember
where an event occurs within an allocentric place have
been shown to be highly dependent on the hippocampus
[43,55,56]. In contrast, findings from several lesion and
imaging studies suggest that the ability to recognize an
object that was part of a previous recent event is not
hippocampus dependent but relies on the perirhinal cor-
tex [43,55,57,58]. In this context, our data therefore
indicate that chronic neuroinflammation impaired hip-
pocampus-dependent but not hippocampus-independent
cognition. This behavioral phenotype is highly consistent
with the fact that neuroinflammation is primarily dis-
tributed within the hippocampus in our model [11,15]
and further demonstrates the high vulnerability of the
hippocampal formation toward neuroinflammation, as is
also the case in humans. Importantly, the cognitive defi-
cits observed in this study were observed up to 3 weeks
after LPS infusion ended, which is in accord with our
recent study showing that neuroinflammation persists
for at least 2 months following termination of LPS-infu-
sion [13]. Taken together, our data suggests that, once
initiated, neuroinflammation time-dependently persists,
significantly impacts neuronal function and leads to hip-
pocampus-dependent cognitive deficits.
Importantly, chronic neuroinflammation resulted in
both short- and long-term spatial recognition memory
deficits as measured following 5-min and 24-h delays.
Short-term memory relies on synaptic mechanisms that
do not require protein synthesis and is insensitive to
inhibitors of transcription and translation. In contrast,
storage of long-term memory, or memory consolidation,
requires protein synthesis-dependent changes in synap-
tic strength [59-63] and the expression of the plasticity
related immediate early gene Arc [64,65]. Thus, our data
support the concept that both protein synthesis-inde-
pendent and protein synthesis-dependent forms of
synaptic plasticity were altered by chronic neuroinflam-
mation. In addition to its well-known role in inflamma-
tion [17], TNF-a has direct effects on glutamate
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transmission and, notably, has been shown to increase
AMPA receptor surface expression [20,66]. The traffick-
ing of AMPA receptors is thought to underlie, at least
in part, both the rapid form of synaptic plasticity and
long-lasting and protein synthesis-dependent changes in
synaptic strength [67]. In line with previous reports
[68,69], our findings suggest that prolonged induction of
TNF-a during chronic neuroinflammation may contri-
bute to a dysregulation of synaptic homeostasis causing
short-term recognition and long-term spatial memory
deficits.
Inhibition of TNF-a synthesis by DT was able to
restore the 5 min delay spatial recognition memory,
indicating that normalization of TNF-a levels was asso-
ciated with a significant amelioration of synaptic home-
ostasis underlying short-term memory. In contrast,
normalization of TNF-a was not sufficient to restore
the 24 h delay spatial recognition. The difference in the
ability of DT to rescue the 5 min but not 24 h delay
recognition memory likely was not due to variations in
its bioavailability, because the DT intraperitoneal injec-
tions were performed daily at the same time during the
novel place recognition protocol and all tests were con-
ducted at similar hours every day. Interestingly, inhibi-
tion of TNF-a by DT was able to restore both spatial
learning and 24 h retention probe trial performance in
the Morris water maze. The apparent discrepancy
between the rescue by DT of long-term spatial memory
in the Morris water maze but not in the novel place
recognition may be due to differences between these
tasks, such as the nature of the motivation or the
amount of training performed. Indeed, although both
assess long-term spatial memory, the Morris water maze
performance relies on escape behavior, speed and accu-
racy of spatial navigation whereas novel place recogni-
tion relies on a novelty spontaneous preference
paradigm. The amount of training also significantly dif-
fers between these tasks and was more important for
the Morris water maze than for novel place recognition
(see methods). We have recently demonstrated that
additional training in the water maze paradigm can, in
fact, mitigate initial mild cognitive deficits [70]. Finally,
the Morris water maze task was conducted subsequent
to the novel place recognition test and rats possibly
gained ability to process spatial information through
their behavioral training. Thus, any of these variables
could potentially interact with the consequences of DT
treatment in ways that a beneficial effect was evidenced
in the 24 h delay probe trial of the Morris water maze
probe trial but not in the 24 h delay novel place
recognition.
The plasticity-related immediate-early gene Arc and
its protein product are induced in hippocampal neu-
rons following spatial exploration in percentages
similar to those recorded electrophysiologically
[12,71,72]. Arc is involved in the trafficking of AMPA
glutamate receptors [73] and Arc protein is required
in the engagement of durable plasticity processes that
underlie memory consolidation [64,65]. In the present
study, we used the detection of Arc as a reliable
method for monitoring cellular activity reflecting spa-
tial and contextual information processing in response
to behavior (i.e. the Morris water maze probe trial)
[12,14,71]. We previously demonstrated that chronic
neuroinflammation disrupts the expression pattern of
behaviorally-induced Arc in the DG and CA3 after
novel environment exploration [11,12]. Both the DG
and CA3 hippocampal subregions cooperate to effi-
ciently process spatial information [74]. The CA3 area
is thought to be particularly involved in large scale
spatial representation, and lesions of the CA3 causes
extensive spatial processing difficulties [74,75]. Here,
we report that the percentage of pyramidal neurons
expressing Arc in the CA3 area was significantly dys-
regulated in LPS-vehicle rats with impaired memory
performance. Importantly, the beneficial effect of DT
on cognitive function was paralleled by a normaliza-
tion of Arc de novo protein synthesis expression. As
Arc transcription is regulated by AMPA receptors
[76], we can hypothesize that the prolonged TNF-a
increase contributes to the disruption in expression of
behaviorally-induced Arc through a dysregulation of
glutamate signaling homeostasis. It is thus conceivable
that the reduction of TNF-a levels by DT did restore
ideal Arc expression levels necessary to maintain opti-
mal synaptic plasticity. The close correlation between
Arc expression levels and probe trial performance
across all experimental groups further strengthens the
significance of Arc as a reliable molecular marker of
neuronal plasticity related to memory.
Conclusions
The present study demonstrates that inhibition of TNF-
a synthesis by 3,6’-dithiothalidomide reverses hippocam-
pus-dependent cognitive deficits induced by chronic
neuroinflammation. To our knowledge this is the first
time that such an effect was reported. Taken together,
our data support that TNF-a is a critical mediator of
chronic neuroinflammation-induced neuronal dysfunc-
tion and cognitive impairment. Therefore, pharmacolo-
gical strategies aimed at decreasing TNF-a synthesis
may be useful to restore neuronal functions and conse-
quently reduce cognitive deficits during chronic neu-
roinflammation. All together these data suggest that
selectively targeting the TNF-a pathway using a blood
brain barrier-permeable compound could provide an
effective therapeutic approach to several human neuro-
degenerative diseases.
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